• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病患者肝纤维化无创评分系统评估的准确性:系统评价和荟萃分析。

Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

机构信息

Department of Emergency Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

Clinical Evidence Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea.

出版信息

Gut Liver. 2022 Nov 15;16(6):952-963. doi: 10.5009/gnl210391. Epub 2022 Feb 23.

DOI:10.5009/gnl210391
PMID:35193993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9668505/
Abstract

BACKGROUND/AIMS: Several noninvasive scoring systems have been developed to determine the risk of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD). We examined the diagnostic accuracy of the fibrosis-4 (FIB-4) score and NAFLD fibrosis score (NFS) in patients with biopsy-proven NAFLD.

METHODS

For this meta-analysis, various databases including PubMed (MEDLINE), EMBASE, OVID Medline and the Cochrane Library were systematically searched. After the acquired abstracts were reviewed by two investigators, manuscripts were chosen for a full-text examination.

RESULTS

Thirty-six studies evaluating biopsy-proven NAFLD were selected for meta-analysis. A total of 14,992 patients were analyzed. The lower cutoff sensitivity of the FIB-4 score predicting histological fibrosis stage 3 or more (≥F3) was 69%, with specificity of 64%, positive likelihood ratio (LR+) of 1.96, and negative likelihood ratio (LR-) of 0.47. The low baseline sensitivity of the NFS score predicting ≥F3 was 70%, with a specificity of 61%, LR+ of 1.83, and LR- of 0.48. The area under the receiver operating characteristic curve (AUC) values of the FIB-4 score predicting ≥F3 and ≥F2 were 76% and 68%, respectively. The AUC values of the NFS score predicting ≥F3 and ≥F2 were 74% and 60%, respectively.

CONCLUSIONS

The FIB-4 or NFS test can be used to predict the degree of liver fibrosis in NAFLD, and the diagnostic accuracy resulted as relatively high in fibrosis stages of F3 or higher.

摘要

背景/目的:已经开发出几种非侵入性评分系统来确定非酒精性脂肪性肝病 (NAFLD) 中晚期纤维化的风险。我们检查了纤维化 4 评分 (FIB-4) 和 NAFLD 纤维化评分 (NFS) 在经活检证实的 NAFLD 患者中的诊断准确性。

方法

为了进行这项荟萃分析,我们系统地检索了各种数据库,包括 PubMed(MEDLINE)、EMBASE、OVID Medline 和 Cochrane 图书馆。在两名研究人员审查了获得的摘要后,选择了用于全文检查的手稿。

结果

共选择了 36 项评估经活检证实的 NAFLD 的研究进行荟萃分析。共分析了 14992 名患者。FIB-4 评分预测组织学纤维化 3 级或更高(≥F3)的下限灵敏度为 69%,特异性为 64%,阳性似然比 (LR+)为 1.96,阴性似然比 (LR-)为 0.47。NFS 评分预测≥F3 的基线灵敏度较低,为 70%,特异性为 61%,LR+为 1.83,LR-为 0.48。FIB-4 评分预测≥F3 和≥F2 的受试者工作特征曲线下面积 (AUC) 值分别为 76%和 68%。NFS 评分预测≥F3 和≥F2 的 AUC 值分别为 74%和 60%。

结论

FIB-4 或 NFS 试验可用于预测 NAFLD 中肝纤维化的程度,在纤维化阶段 F3 或更高时诊断准确性相对较高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/9668505/c623593e766a/gnl-16-6-952-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/9668505/7f1d94ac96da/gnl-16-6-952-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/9668505/c623593e766a/gnl-16-6-952-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/9668505/7f1d94ac96da/gnl-16-6-952-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/9668505/c623593e766a/gnl-16-6-952-f2.jpg

相似文献

1
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.非酒精性脂肪性肝病患者肝纤维化无创评分系统评估的准确性:系统评价和荟萃分析。
Gut Liver. 2022 Nov 15;16(6):952-963. doi: 10.5009/gnl210391. Epub 2022 Feb 23.
2
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.肥胖和丙氨酸氨基转移酶水平对非酒精性脂肪性肝病患者无创性工具诊断晚期肝纤维化的准确性的影响。
Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.
3
Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的非侵入性纤维化评分系统在非裔美国人和白人患者中的准确性。
Clin Transl Gastroenterol. 2020 Apr;11(4):e00165. doi: 10.14309/ctg.0000000000000165.
4
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.在退伍军人健康管理局中识别非酒精性脂肪性肝病的肝纤维化程度。
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
5
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.在识别非酒精性脂肪性肝病(NAFLD)及NAFLD相关肝硬化的临床显著阶段方面,机器学习模型优于非侵入性检测。
Hepatology. 2023 Feb 1;77(2):546-557. doi: 10.1002/hep.32655. Epub 2022 Aug 9.
6
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.非酒精性脂肪性肝病(NAFLD)合并 2 型糖尿病患者肝纤维化的无创评估。
Hepatology. 2023 Jul 1;78(1):195-211. doi: 10.1097/HEP.0000000000000351. Epub 2023 Mar 17.
7
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.年龄作为晚期非酒精性脂肪性肝病纤维化准确无创诊断的混杂因素。
Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11.
8
Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.Hepamet纤维化评分系统的开发与验证——一种用于识别非酒精性脂肪性肝病伴晚期纤维化患者的简单无创检测方法
Clin Gastroenterol Hepatol. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11.
9
Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.基于四项因素(FIB-4)评分或 Forns 指数的成人慢性丙型肝炎肝纤维化分期。
Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD011929. doi: 10.1002/14651858.CD011929.pub2.
10
Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease.非侵入性评分对儿科脂肪性肝病的肝纤维化组织学预测效果不佳。
J Pediatr Gastroenterol Nutr. 2024 Jan;78(1):27-35. doi: 10.1002/jpn3.12068. Epub 2023 Dec 29.

引用本文的文献

1
Screening for metabolic-associated fatty liver disease in type 2 diabetes patients using non-invasive scores and ultrasound: a cross-sectional study in Egypt.使用非侵入性评分和超声对2型糖尿病患者进行代谢相关脂肪性肝病筛查:埃及的一项横断面研究。
BMC Gastroenterol. 2025 Sep 15;25(1):639. doi: 10.1186/s12876-025-03844-9.
2
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050.45岁及以上成年人中与非酒精性脂肪性肝炎相关的肝癌的全球、区域和国家负担:来自全球疾病负担研究(GBD)2021的分析及到2050年的预测
Front Nutr. 2025 Aug 19;12:1651357. doi: 10.3389/fnut.2025.1651357. eCollection 2025.
3

本文引用的文献

1
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南:非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
2
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.非酒精性脂肪性肝病患者肝纤维化无创性检查诊断准确性的个体患者数据分析荟萃研究。
Gut. 2022 May;71(5):1006-1019. doi: 10.1136/gutjnl-2021-324243. Epub 2021 May 17.
3
External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population.
Xietu Hemu Prescription Improves Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Cohort Study.
泻土和木方改善代谢功能障碍相关脂肪性肝病:一项真实世界队列研究
J Multidiscip Healthc. 2025 Jul 29;18:4377-4389. doi: 10.2147/JMDH.S522519. eCollection 2025.
4
Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.血小板衍生生长因子受体-β作为埃及代谢相关脂肪性肝病糖尿病患者肝纤维化预测的无创生物标志物
BMC Gastroenterol. 2025 Jul 17;25(1):524. doi: 10.1186/s12876-024-03542-y.
5
Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests.通过血清学非侵入性检测识别的疑似代谢相关脂肪性肝病(MASLD)个体中晚期肝纤维化筛查的成本效益
Sci Rep. 2025 Jul 7;15(1):24186. doi: 10.1038/s41598-025-08434-z.
6
Predicting Fibrosis Stage in MASH: The Role of Total Metabolic Syndrome Score and MMP-1.预测非酒精性脂肪性肝炎中的纤维化阶段:总代谢综合征评分和基质金属蛋白酶-1的作用。
Medicina (Kaunas). 2025 Jun 17;61(6):1102. doi: 10.3390/medicina61061102.
7
Association between liver fibrosis's noninvasive scores and retinal imaging changes: insights from NHANES.肝纤维化无创评分与视网膜成像变化之间的关联:来自美国国家健康与营养检查调查(NHANES)的见解
J Health Popul Nutr. 2025 Feb 28;44(1):56. doi: 10.1186/s41043-025-00805-6.
8
Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study.脂肪性肝病对慢性乙型肝炎患者肝功能及肝纤维化的影响:一项横断面研究
Front Med (Lausanne). 2024 Nov 21;11:1481051. doi: 10.3389/fmed.2024.1481051. eCollection 2024.
9
Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study.Forns 指数和脂肪肝指数与血糖、糖尿病前期和 2 型糖尿病的指标相关,但 FIB-4 无关:马斯特里赫特研究分析。
BMJ Open Gastroenterol. 2024 Nov 29;11(1):e001466. doi: 10.1136/bmjgast-2024-001466.
10
Diagnostic performance of new BAST score versus FIB-4 index in predicating of the liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.新型 BAST 评分与 FIB-4 指数在预测代谢相关脂肪性肝病患者肝纤维化中的诊断性能比较。
Eur J Med Res. 2024 Sep 14;29(1):459. doi: 10.1186/s40001-024-02032-x.
基于以西班牙裔为主的非酒精性脂肪性肝病人群的四项即时检测非侵入性评分对预测进展性肝纤维化的外部验证。
Dig Dis Sci. 2021 Jul;66(7):2387-2393. doi: 10.1007/s10620-020-06501-1. Epub 2020 Aug 5.
4
Clinical profile of non-alcoholic fatty liver disease in nonobese patients.非肥胖患者非酒精性脂肪性肝病的临床特征。
J Gastroenterol Hepatol. 2021 Jan;36(1):257-261. doi: 10.1111/jgh.15154. Epub 2020 Jul 5.
5
Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.基于肠道微生物组的方法与简单的无创工具相比,预测非酒精性脂肪性肝病的肝纤维化程度。
Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.
6
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.无创性纤维化评分在经活检证实的非酒精性脂肪性肝病的 2 型糖尿病患者中检测晚期纤维化的准确性。
J Clin Gastroenterol. 2020 Nov/Dec;54(10):891-897. doi: 10.1097/MCG.0000000000001339.
7
Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds.非侵入性肝纤维化评分在病态肥胖患者中的表现:相同评分,不同阈值。
Obes Surg. 2020 Jul;30(7):2538-2546. doi: 10.1007/s11695-020-04509-0.
8
Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.基于 Fibroscan 的评分预测肥胖的非酒精性脂肪性肝病患者的显著肝纤维化。
Obes Surg. 2020 Apr;30(4):1249-1257. doi: 10.1007/s11695-019-04192-w.
9
The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider.非酒精性脂肪性肝病患者的诊断及初始诊疗方法:基层医疗服务提供者的作用
Gastroenterol Hepatol Bed Bench. 2019 Fall;12(4):267-277.
10
Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.基于新型列线图的非酒精性脂肪性肝病患者显著肝纤维化的个体化风险预测。
United European Gastroenterol J. 2019 Oct;7(8):1124-1134. doi: 10.1177/2050640619868352. Epub 2019 Jul 30.